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Background:	There	is	limited	information	on	the	presentation	and	characteristics	of	psychotic	illness	
experienced	by	people	with	autism	spectrum	disorder	(ASD).	
Aims:	To	describe	autistic	and	psychotic	phenomenology	in	a	group	of	individuals	with	co-morbid	
ASD	and	psychosis	(ASD-P)	and	compare	with	populations	affected	by	either,	alone.	
Method:	We	studied	116	individuals	with	ASD-P.	We	compared	features	of	their	ASD	with	people	
with	ASD	and	no	co-morbid	psychosis	(ASD-NP)	and	clinical	characteristics	of	psychosis	to	people	
with	psychosis	only	(P).			
Results:	ASD-P	individuals	had	more	diagnoses	of	atypical	psychosis	and	fewer	of	schizophrenia	
compared	to	P	individuals.	ASD-P	had	fewer	stereotyped	interests/behaviours	compared	to	ASD-NP.	
Rates	of	medication	use	are	also	given	for	ASD-P.	
Conclusions:	Our	data	show	there	may	be	a	specific	subtype	of	ASD	linked	to	co-morbid	psychosis.	
The	results	support	findings	that	psychosis	in	people	with	ASD	is	often	atypical,	particularly	
regarding	affective	disturbance.	
Declaration	of	interest:	none.	
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Introduction	
The	relationship	between	psychotic	illnesses	(particularly	schizophrenia)	and	autism	
spectrum	disorder	(ASD)	is	complex,	with	suggestions	that	there	is	substantial	overlap	between	the	
two	conditions	(1),	although	they	differ	considerably	in	the	age	of	onset,	with	the	former	usually	first	
becoming	apparent	in	adolescence	and	early	adulthood	and	the	latter	in	early	childhood.	People		
with	ASD	may	experience	co-morbid	psychotic	illnesses	such	as	schizophrenia	and	bipolar	disorder	
(we	have	termed	this	comorbidity	‘ASD-P’),	with	studies	indicating	rates	as	high	as	28%	(2).	Selten	et	
al.	concluded	from	a	recent	population-based	study	of	people	with	an	ASD	that	their	odds	of	having	
a	co-morbid	psychosis	were	between	5.6-5.8,	depending	on	the	type	of	psychosis	(3).	Another	recent	
study	has	also	reported	epidemiological	evidence	for	a	connection	between	developmental	
disorders	manifest	in	childhood	and	psychotic	experiences	in	adolescence	(4).	Thus,	despite	the	
difficulties	of	researching	in	this	area,	evidence	is	accumulating	that	individuals	with	ASD	are	at	
greater	risk	of	developing	psychotic	illnesses	than	those	in	the	general	population.	
Descriptions	of	the	phenomenology	of	psychotic	illness	in	ASD	come	from	case	studies	and	
small	case	series	(e.g.	(5)),	but	these	have	been	unsystematic,	and	it	remains	uncertain	how	
psychotic	illness	presents	in	the	ASD	population.	One	possibility	is	that	there	may	be	a	subtype	of	
ASD	that	carries	a	higher	risk	of	psychotic	illness	driven	by	common	genetic	variants	(probably	copy	
number	variants	rather	than	single	nucleotide	polymorphisms)	(see	(1)	for	a	summary).	If	this	were	
the	case,	people	with	ASD	who	develop	psychosis	might	differ	significantly	in	the	presentation	of	
their	ASD	from	those	without	psychosis,	and	that	the	psychotic	illness	would	have	similar	
characteristics	across	people	with	ASD.	This	is	further	complicated	by	the	fact	that	features	of	ASD	
could	be	misdiagnosed	as	psychotic	symptoms	with	difficulties	in	reading	others’	intentions	
resembling	paranoia,	difficulties	in	expressive	communication	resembling	thought	disorder,	and	
‘melt	downs’	resembling	catatonia	(6).	Alternatively,	the	phenomenological	presentation	of	
psychosis	in	people	with	ASD	may	itself	be	different	or	these	psychopathological	alternatives	may	
simply	be	epiphenomena	of	different	constructs	and	language	from	separate	literatures	applied	to	
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the	same	mental	phenomena.	To	better	understand	this	relationship	between	ASD	and	psychotic	
illness,	we	report	below	on	a	cross-sectional	study	of	people	with	ASD-P.	For	genetic	reasons	or	
because	of	diagnostic	confusion,	we	hypothesise	that	in	individuals	with	ASD-P	both	conditions	
would	take	a	recognisably	distinct	form,	different	from	the	manifestations	of	either	ASD	or	psychotic	
illness	as	it	manifests	in	singly-affected	populations.	
	
Methods	
Written	informed	consent	was	obtained	from	all	participants	prior	to	study	procedures	
taking	place.	Individuals	aged	16	or	older	were	considered	eligible	to	give	consent	for	themselves.	
Where	participants	were	found	to	lack	capacity	to	consent	to	participate	in	research,	advice	from	an	
informant	who	knew	them	well,	such	as	a	family	member,	was	obtained	in	accordance	with	UK	law.	
Recruitment	and	data	collection	for	the	ASD-P	group	took	place	between	January	2010	and	June	
2013.	The	Cambridgeshire	3	Research	Ethics	Committee,	United	Kingdom,	approved	the	project.	
Participants	and	Measures	
The	total	number	of	participants	with	ASD	and	co-morbid	psychosis	(the	ASD-P	group)	was	
116	(M=89,	F=27).	They	were	initially	identified	and	referred	to	the	study	by	clinicians	in	services	
across	the	UK,	through	charities	and	by	self-referral.		
The	sample	size	in	this	study	represents	the	maximum	number	of	eligible	individuals	
recruited	within	a	constrained	time	period	and	was	not	determined	by	formal	sample-size	
calculation.	Recruitment	was	undertaken	by	a	number	of	different	agencies,	and	it	was	not	possible	
to	know	the	number	of	individuals	invited	to	take	part	but	who	did	not	respond.	None	of	those	who	
consented	to	participate	withdrew.			
	
Eligibility	criteria	for	ASD-P	group	
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Participants	were	required	to:	
• have	a	clinical	diagnosis	of	ASD	at	the	time	of	referral	to	the	study,	or	
• meet	criteria	on	the	Autism	Diagnostic	Observation	Schedule	(ADOS)(7)	at	the	time	
of	involvement	in	the	study,	or	
• meet	criteria	on	the	Autism	Diagnostic	Interview-Revised	(ADI-R)	(8)	for	a	life-time	
diagnosis.	A	maximum	of	1	point	below	threshold	on	any	one	of	three	ADI-R	
diagnostic	scales	was	accepted	as	indicative	of	ASD	for	individuals	with	no	clinical	
diagnosis	of	ASD,	as	in	all	cases	of	referral	ASD	was	suspected	by	the	person’s	
clinical	team.	Details	of	the	participants’	age	at	administration	of	the	ADI-R	was	
obtained;	all	but	one	case	the	ADI-R	was	conducted	on	enrolment	in	the	study.	
History	of	a	co-morbid	psychotic	illness	was	determined	in	two	stages.	Participants	were	
initially	included	if	they	had	a	prior	clinical	diagnosis	of	psychotic	illness	or	gave	an	account	of	an	
episode	that	was	clearly	psychotic.	Their	participation	was	subsequently	confirmed	if	psychotic	
symptoms	were	elicited	by	the	first	author	using	the	Diagnostic	Interview	for	Psychosis	(DIP)	(9)	or	
the	Psychiatric	Assessment	Schedule	for	Adults	with	Developmental	Disabilities	(Mini	PAS-ADD)	(10).	
Both	instruments	can	be	used	to	generate	diagnoses	using	the	Operational	Criteria	Checklist	
(OPCRIT)	(11).	The	Mini	PAS-ADD	was	used	when	individuals	had	an	intellectual	disability	and	were	
unable	to	fully	self-report	their	experiences.	In	two	cases,	neither	the	participant	nor	an	informant	
was	available.	For	these	participants,	the	OPCRIT	was	completed	using	the	person’s	notes,	either	by	
the	first	author	or	a	trained	member	of	a	research	network.	Diagnoses	were	generated	using	
International	Classification	of	Diseases-10	(ICD-10)	(12),	Diagnostic	and	Statistical	Manual	–	4th	
Edition	(Text	Revision)	(DSM-IV-TR)	(13)	and	Research	Diagnostic	Criteria	(RDC)	(14)	algorithms	in	the	
OPCRIT.	Participants	were	considered	to	have	research-significant	psychosis	if	they	met	criteria	for	a	
disorder	with	features	of	psychosis	(ICD-10	F20-F39	diagnoses	that	include	psychosis	in	the	
description)	on	any	one	of	the	three	algorithms.	
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In	practice,	there	was	little	confusion	between	symptoms	of	ASD	and	of	psychosis	in	our	
participants.	Psychosis	was	always	associated	with	a	change	from	previous	functioning	and	rarely	
involved	a	person’s	special	interests	or	repetitive	behaviours.	Additionally,	the	psychotic	illnesses	
described	had	all	been	treated	by	experienced	mental	health	professionals.	
Verbal	IQ	(VIQ)	was	also	collected	for	participants	using	the	Wechsler	Abbreviated	Scales	of	
Intelligence	(WASI)	(15).		
ASD	comparison	group	
ADI-R	data	were	also	available	from	a	group	of	individuals	with	both	clinically	and	ADI-R-,	
ADOS-	or	Adult	Asperger	Assessment	(AAA)	(16)	confirmed	ASD	and	without	a	known	history	of	
psychotic	illnesses,	substance-use	disorders,	epilepsy,	or	genetic	disorders	associated	with	autism	
(N=69;	males=32,	females=37).	They	were	recruited	via	the	Cambridge	arm	of	the	Medical	Research	
Council	Autism	Imaging	Multicentre	Study	(MRC	AIMS)	project	(17),	and	are	termed	the	ASD-No	
Psychosis	(ASD-NP)	group.	VIQ	scores,	collected	via	the	WASI,	were	also	available	for	this	group.	
Psychotic	comparison	group	
	 The	comparison	group	with	psychosis	only	came	from	the	ÆSOP	study,	a	three	centre,	
prospective	survey	of	first	onset	psychoses	carried	out	in	the	UK	between	1997	and	1999.	It	
comprised	of	568	individuals	with	clinically	relevant	psychosis.	Full	details	of	the	cohort	are	available	
elsewhere	(18).	
Missing	data	
Of	the	116	participants,	13	were	missing	verbal	IQ	data,	32	were	missing	ADI-R	data,	and	3	were	
missing	OPCRIT	data.	A	subset	of	75	participants	had	full	data	available	and	were	used	for	
comparison	of	ASD	traits	(M=63,	F=12).	This	subset	did	not	differ	significantly	from	the	initial	sample	
in	terms	of	gender,	diagnosis,	or	verbal	IQ.	However,	they	were	significantly	younger	than	those	with	
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missing	data	(t(42)=4.9,	p<0.001),	normally	because	developmental	information	from	parents	was	
often	unavailable	in	older	participants	due	to	death,	estrangement,	or	non-participation.	
Procedures	
The	relative	proportions	of	different	types	of	psychosis	in	the	study	population	(DSM-IV-TR	
diagnoses)	were	compared	with	the	relative	proportions	of	different	categories	of	psychoses	
reported	in	the	ÆSOP	study	(18),	excluding	those	with	substance-induced	psychosis.	These	
categories	were	defined	as	follows:	
• Affective	psychosis	
o DSM-IV	296.x4,	296.4,	296.89	
• Schizophrenia	(including	schizoaffective	and	schizophreniform	disorders)	
o DSM	IV	295.xx	
• Other	psychosis	(called	non-affective	psychosis	in	the	ÆSOP	study)	
o DSM-IV	297.xx,	298.8,	298.9	
Substance-induced	psychosis	is	not	a	diagnosis	generated	by	the	OPCRIT	and	therefore	none	of	the	
participants	with	ASD-P	could	be	given	this	diagnosis.		However,	while	substance	use	did	occur	in	
some	individuals	in	the	ASD-P	group	around	the	time	of	first	onset	of	illness,	there	were	no	cases	
where	there	was	a	clear	role	of	substance	use	in	aetiology.		
	 Data	were	also	reported	regarding	the	characteristics	and	course	of	the	psychopathology	
specifically	experienced	by	individuals	in	the	ASD-P	group	together	with	details	of	medication	
prescription.	A	more	detailed	description	of	the	types	of	psychotic	experiences	of	participants	is	
given	in	Supplement	1.		
	
Statistical	analysis	
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Variables	were	compared	between	groups	using	Fisher’s	exact	or	t-tests	as	appropriate.	Multivariate	
analysis	of	covariance	(MANCOVA)	was	used	to	test	for	differences	between	ASD-P	and	ASD-NP	
groups	on	the	ADI-R	diagnostic	algorithm	domain	scores	for	qualitative	abnormalities	in	reciprocal	
social	interaction	(Scale	A),	qualitative	abnormalities	in	communication	(Scale	B	(verbal)),	and	
restricted,	repetitive,	and	stereotyped	patterns	of	behaviour	(Scale	C).	To	give	more	insight	into	the	
relationships	between	the	scales	and	the	covariates,	we	then	fitted	separate	regression	models	
between	each	of	the	scales	A-C	and	the	covariates.	Variables	included	as	covariates	were	gender,	
age	at	which	the	ADI-R	was	conducted,	and	VIQ.	A	Bonferroni	correction	to	compensate	for	these	
multiple	analyses	was	applied,	with	p-values	of	0.017	(0.05/3)	or	smaller	considered	significant.	
	
Results 
Characteristics	of	the	psychotic	illness	in	the	ASD-P	group	(N=116)	
Age	of	onset	of	psychotic	illness	varied	considerably,	with	some	individuals	reporting	onset	
in	early	childhood	or	in	middle	age	(range:	6-55	years,	two	over	45,	six	younger	than	12).	The	rate	of	
onset	of	illness	was	also	variable,	with	the	greatest	number	(42%)	reporting	an	insidious	(greater	
than	six	months)	decline	from	previous	functioning.	Impairment	during	illness	was	also	variable,	but	
71%	of	participants	reported	severe	impairment	(complete	lack	of	normal	functioning	for	at	least	2-3	
days,	or	any	admission).	The	majority	(53%)	had	had	at	least	one	episode	of	illness	lasting	more	than	
two	years,	although	much	shorter	episodes	were	also	reported.	
Mood	and	psychotic	symptoms	were	grouped	into	broad	categories.	For	mood	symptoms,	
the	DSM-IV	defining	criteria	for	major	depressive	or	manic	episode	were	used	(presence	of	low	
mood	and/or	loss	of	pleasure	for	depression,	elevated	mood	and/or	irritability	for	mania).	Figure	1	
shows	the	rates	of	each	symptom	category	in	the	ASD-P	sample.	Ninety-nine	(85.3%)	participants	
had	a	lifetime-ever	experience	of	core	affective	symptoms	(either	depression	and/or	mania)	and	74	
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(63.4%)	people	reported	that	affective	symptoms	occurred	concurrently	with	psychotic	symptoms,	
although	this	was	not	associated	with	high	rates	of	DSM-IV-TR	affective	psychotic	illness	(see	below).	
There	was	agreement	between	two	or	more	diagnostic	systems	in	79.3%	of	cases.	The	most	
frequent	concordant	diagnosis	was	psychosis	not	otherwise	specified,	in	31.9%	of	cases.	The	second	
most	frequent	concordant	diagnosis	was	schizophrenia	(20.7%).	All	other	concordant	diagnoses	
occurred	at	a	frequency	of	less	than	10%.	
	
Diagnoses	of	psychosis	(N	ASD-P	=	71,	N	ÆSOP	=	538)	
Seventy-one	ASD-P	participants	had	a	DSM-IV-TR	diagnosis	of	psychotic	illness,	and	these	
diagnoses	were	compared	with	the	ÆSOP	study.	There	were	significant	differences	between	the	
relative	proportions	of	different	diagnoses	between	the	ÆSOP	study	and	the	current	study	(Fisher’s	
exact	test,	p<0.01)	(see	Figure	2).	Affective	psychoses	occurred	with	similar	frequency	in	the	two	
samples	(Fisher’s	exact	test,	p=0.38).	Schizophrenia	was	less	frequent	in	the	ASD-P	group	(Fisher’s	
exact	test,	p<0.01),	and	other	psychoses	were	proportionately	much	more	common	in	the	ASD-P	
group	(Fisher’s	exact	test,	p<0.01).	This	difference	seems	to	have	been	caused	by	the	large	number	
of	participants	in	the	ASD-P	group	with	a	diagnosis	of	psychotic	disorder	not	otherwise	specified	(P-
NOS)	(44%).	Rates	of	P-NOS	were	not	available	for	the	ÆSOP	study	sample,	so	direct	statistical	
comparison	is	not	possible.	
INSERT	FIGURES	1	AND	2	ABOUT	HERE	
Medication	prescription	(N	ASD-P	=	92)	
Information	about	regular	psychotropic	medication	use	at	the	time	of	the	study	was	
available	for	92	participants.	Only	four	of	these	participants	were	not	taking	psychotropic	
medication:	one	had	stopped,	and	three	had	never	been	prescribed	them.	Of	the	remainder,	71	
(77%	of	those	on	whom	medication	data	were	available)	were	taking	at	least	one	antipsychotic	
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medication,	with	9%	(6/71)	being	prescribed	clozapine.	Forty-six	(50%)	were	taking	a	single	
medication,	while	32	(35%)	were	taking	two	medications	and	10	(11%)	were	taking	three.	See	
Supplement	2	for	a	figure	showing	medication.	
Among	those	people	taking	two	or	more	medications,	the	most	common	combination	was	
an	antidepressant/mood	stabiliser	and	one	or	two	antipsychotics.	Three	participants	were	also	
prescribed	one	or	more	benzodiazepines	in	addition	to	an	antipsychotic.	Two	were	prescribed	
procyclidine.	Three	participants	volunteered	that	they	had	either	idiosyncratic	reactions	or	were	
unusually	sensitive	to	psychotropics.	Data	regarding	other	medications	beyond	those	reported	here	
were	not	available.	
	
Autistic	Features	(N	ASD-P=75)	
INSERT	TABLE	1	HERE	
Differences	between	the	ASD-P	participants	with	full	data	(N=75)	and	ASD-NP	(N=69)	groups	
are	reported	in	Table	1.	Compared	to	the	ASD-NP	group,	the	ASD-P	group	had	significantly	fewer	
females,	was	significantly	slightly	older	when	the	ADI-R	was	completed,	and	had	a	significantly	lower	
VIQ.	Thus,	gender,	age	at	administration	of	the	ADI-R,	and	VIQ	were	included	in	the	analysis	as	
covariates.	
Raw,	unadjusted	differences	between	groups	on	the	ADI-R	scales	were	all	less	than	one	scale	
point	and	not	significantly	different	(p>0.1).	The	results	of	the	MANCOVA	are	shown	in	Table	2	and	
indicate	a	significant	effect	of	group	membership	on	Scale	C	score.	
	
INSERT	TABLE	2	ABOUT	HERE	
	
In	the	subsequent	univariate	analyses	by	scale,	group	membership	only	had	a	significant	
effect	(at	the	p=0.006	level)	on	Scale	C.	The	largest	effect	of	group	membership	(as	judged	by	partial	
η²)	was	seen	on	Scale	C;	within	the	univariate	regression	on	Scale	C,	group	membership	had	the	
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largest	effect	(η²=0.05,	between	a	small	and	medium	effect	size	–	see	(19)).	Focusing	on	scale	C,	
neither	VIQ	nor	age	significantly	affected	scores	when	the	conservative	Bonferroni	corrected	
significance	level	was	used.	The	ASD-P	group	scored	1.4	points	less	on	average,	a	moderate	effect	
size	in	terms	of	Cohen’s	D	(Scale	C	SD=2.5;	D=1.4/2.5≈0.6).	When	another	regression	model	was	
fitted	that	included	all	second	order	interaction	term,	no	interactions	approached	significance	(all	p	
values	>0.1).	
Discussion	
Summary	of	results	
Our	results	indicate	that	individuals	with	ASD	who	have	also	developed	a	co-morbid	
psychotic	illness	differ	significantly	in	their	autistic	phenotypic	profile	from	individuals	with	ASD	
alone.	The	ASD-P	group	showed	significantly	fewer	lifetime	stereotyped,	repetitive,	or	restrictive	
interests/behaviours.	In	addition,	the	diagnosis	profile	in	the	ASD-P	group	differed	to	that	of	
individuals	with	psychosis	only.	ASD-P	individuals	had	lower	rates	of	schizophrenia	and	higher	rates	
of	P-NOS.	Our	description	of	the	psychosis	seen	in	the	ASD-P	group	came	from	the	largest	sample	of	
its	kind	known	to	us.		
	
Meaning	of	the	results	
Difficulties	in	diagnosing	psychotic	illness	in	people	with	ASD	have	been	highlighted	(6).	
Others	have	commented	on	the	misdiagnosis	of	ASD	as	schizophrenia	(21).	Therefore,	careful	steps	
were	taken	in	the	current	study	to	ensure	only	individuals	with	clear	diagnoses	of	both	disorders	
were	included.	This	took	place	in	two	stages	–	first,	by	recruitment	from	clinical	services	experienced	
in	the	diagnosis	and	treatment	of	psychosis,	and	second,	by	confirming	both	ASD	characteristics	and	
mental	health	history	using	standardised	and	well-validated	instruments.	It	is	also	important	to	
acknowledge	that	the	phenomenological	data	in	this	study	were	rated	only	once	so,	despite	the	use	
of	standardised	measures	and	diagnostic	algorithms,	rater	bias	may	have	affected	the	results.	
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The	results	indicate	that	the	spectrum	of	psychotic	illness	experienced	by	adults	with	ASD	
may	be	different	from	that	experienced	by	the	population	without	a	diagnosis	of	ASD.	This	is	evident	
from	the	different	distribution	of	DSM-IV-TR	diagnoses	and	the	high	number	of	P-NOS	cases	(Figure	
2).	The	duration	of	illness	reported	by	individuals	with	ASD	in	this	study	generally	did	not	meet	the	
duration	criteria	for	DSM-IV-TR	schizophrenia	(minimum	of	six	months	disturbance	with	one	month	
of	active	symptoms),	indicating	a	more	acute,	transient	course	than	that	seen	in	the	general	
population	(similar	to	that	reported	elsewhere	(22)).	This	atypical	diagnostic	distribution	for	
psychotic	illness	is	supported	by	observations	from	studies	of	mental	health	problems	in	people	with	
ASD	previously	reported	(23).	It	is	possible	that	this	difference	is	explained	by	individuals	with	ASD	
responding	differently	to	the	questions	used	to	derive	psychotic	diagnoses	since	the	measures	used	
were	not	standardised	for	use	with	people	who	have	ASDs.	However,	the	descriptions	of	symptoms	
obtained	from	participants,	and	referrals	from	clinical	services	suggest	there	is	validity	in	these	
results.	
	 The	prominence	of	affective	symptoms	in	people	with	concurrent	ASD	and	psychosis	is	
informative	in	light	of	family	medical	histories.	For	example,	there	are	higher	rates	of	bipolar	
disorder	in	the	families	of	people	with	Asperger’s	syndrome	(24),	indicating	plausible	shared	genetic	
risks	of	affective	disturbance	among	some	people	on	the	autism	spectrum.	This	is	supported	by	
recent	research	showing	the	increased	risk	of	ASD	in	families	with	a	history	of	schizophrenia	and/or	
bipolar	disorder	(25).	A	family	history	of	depression	or	anxiety	is	also	more	common	in	people	with	
ASD	than	in	the	general	population	(26).	Thus,	it	seems	likely	that	major	mood	disorders	and	
psychosis	share	risk	pathways	with	ASD,	as	potentially	diverse	as	having	a	common	genetic	
mechanisms	or	because	of	the	long-term	experience	and	stress	of	having	an	ASD	increases	the	risks	
of	developing	mood	disorders	in	adolescence	and	adulthood.	Both	of	these	elements	are	consistent	
with	a	stress-vulnerability	model	of	affective	disorders	and/or	psychotic	illness	(27).	In	addition,	the	
considerable	clinical	heterogeneity	of	the	psychotic	illness	we	report	in	the	ASD-P	group	also	argues	
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against	there	being	a	unique	form	of	psychotic	illness	linked	to	ASD	and	consequent	upon	a	major	
effect	of	a	single	genetic	variant	predisposing	to	both	conditions.		
We	propose	that	our	observations	support	the	existence	of	an	underlying	
neurodevelopmental	vulnerability	to	developing	psychosis	in	some	people	with	ASD.	We	suggest	
that	this	is	driven	by	an,	as-yet,	poorly	understood	genetic	mechanism,	compounded	by	elevated	
rates	of	depression	and	anxiety,	perhaps	linked	to	the	stress	of	sensory	differences,	social	
difficulties,	unemployment,	bullying,	or	other	problems	faced	by	many	people	with	ASD.	There	is	
currently	little	standardised	stressful	life	event	data	from	an	ASD	population,	and	this	is	an	
important	area	of	future	research.	
	 Beyond	potentially	atypical	presentations	of	psychosis,	some	support	for	there	being	a	
biological	vulnerability	to	psychotic	illness	comes	from	our	observations	that	individuals	with	this	co-
morbidity	tend	to	have	a	different	pattern	of	autistic	characteristics.	The	finding	that	they	have,	on	
average,	significantly	fewer	restricted,	repetitive,	and	stereotyped	behaviours	and	interests	than	
those	with	ASD	alone	is	informative	on	a	number	of	levels.	It	may	represent	the	genetic	fractionation	
of	the	parts	of	the	autism	triad	(28),	and	could	suggest	that	the	genetic	risk	factors	for	social-
communication	difficulties	share	a	greater	association	with	genetic	risk	factors	for	psychosis	(e.g.,	
FOXP2	(29))	than	restricted	and	repetitive	behaviours.	
	
Diagnostic	systems	
While	a	detailed	discussion	of	the	differences	between	diagnostic	systems	is	beyond	the	scope	of	
this	report,	it	is	worth	highlighting	that	individuals	with	ASD,	who	may	experience	psychosis	
differently	from	the	general	population,	do	not	appear	to	fit	easily	into	existing	diagnostic	
categories.	It	has	been	well-described	that	there	is	to	some	extent	a	lack	of	agreement	between	
diagnostic	systems	(e.g.(30)),	which	is	why	the	current	study	chose	a	concordance	approach	to	the	
inclusion	of	participants,	rather	than	relying	on	any	one	diagnostic	system.	In	particular,	the	lack	of	
an	exclusion	criterion	for	affective	symptoms	in	ICD-10-defined	schizophrenia	highlighted	by	(30)	
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may	be	relevant	to	people	with	ASD	and	psychosis,	as	it	appears	that	affective	symptoms	are	
prominent	in	the	individuals	reported	here.	It	also	suggests	that	diagnosing	psychosis	in	people	with	
ASD	may	require	particular	care	on	the	part	of	clinicians	and	a	critical	appraisal	of	the	diagnostic	
systems	used	in	their	practice.	Unfortunately,	this	may	have	implications	for	treatment	that	is	based	
on	diagnosis,	as	individuals	with	ASD	may	be	inadequately	served	if	only	a	single	diagnostic	system	is	
relied	upon	to	determine	eligibility	for	treatment,	particularly	where	a	decision	is	made	to	offer	or	
exclude	treatment	based	on	a	diagnosis	of	psychosis	using	a	single	diagnostic	system.	
	
Models	of	the	relationship	between	ASD	and	psychosis	
	 In	light	of	this	sample,	it	may	be	important	to	reconsider	models	that	have	been	proposed	to	
describe	the	relationships	between	ASD	and	psychosis.	In	our	view,	a	possible	model	would	
emphasise	the	dimensional	nature	of	mood	symptoms,	psychotic	symptoms,	and	autistic	
characteristics.	Our	results	suggest	that	the	overlap	between	ASD	and	schizophrenia	(as	opposed	to	
psychosis	more	broadly)	may	be	limited.	Indeed,	some	have	questioned	whether	schizophrenia	
might	be	considered	part	of	the	autism	spectrum	(1).	If	it	is,	it	most	likely	represents	a	somewhat	
different	part	of	the	spectrum	from	the	affective	psychosis	that	predominated	in	this	current	
sample.	
	
Generalisability	and	limitations	
Our	sample	may	not	be	representative	of	all	people	who	have	ASD	and	psychotic	illness.	
Sampling	was	conducted	as	widely	as	possible	throughout	England,	with	a	small	number	of	
participants	from	other	parts	of	the	UK,	but	was	not	systematic.	Population-based	studies	have	
identified	autistic-like	features	in	the	developmental	histories	of	people	who	develop	schizophrenia	
(31)	and,	in	retrospective	studies	of	people	with	schizophrenia,	ASD	is	diagnosed	frequently	(32).		
There	may	be	lower	numbers	of	people	meeting	criteria	for	schizophrenia	in	this	study	because	of	
self-selection	bias.	Factors	such	as	negative	symptoms,	poorer	outcome,	or	lower	IQ	(33),	may	have	
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disproportionately	discouraged	certain	individuals	from	participating.	A	population-based	
epidemiological	study	with	the	resolution	to	examine	properly	both	psychotic	and	autistic	features	in	
adulthood	would	be	costly	and	difficult	to	conduct,	given	difficulties	with	diagnostic	uncertainty	
when	two	spectrums	overlap,	but	might	settle	the	issue.	Currently,	some	of	the	best	evidence	with	a	
developmental	perspective	is	a	population-based	study	that	found	an	association	between	
childhood	neurodevelopmental	diagnoses,	including	ASD,	and	psychotic	experiences	in	adolescence,	
an	association	not	mediated	by	lower	IQ	(3).	There	is	also	a	birth	cohort	study	showing	very	similar	
results	(34).	These	are	methodologically	strong	studies	with	robust	results.	However,	more	research	
will	be	needed	to	further	describe	psychosis	in	people	with	ASD	and	to	understand	its	relationship	to	
psychosis	seen	in	people	without	ASD.		
A	limitation	of	this	study	is	the	lack	of	comparison	samples	collected	for	the	purpose	of	
directly	comparing	with	the	ASD-P	group.	Relying	on	previously	published	data	and	samples	meant	
that	at	times,	methods	used	for	analysis	were	less	robust	than	they	would	have	been	with	a	well-
matched	sample.	The	nature	of	the	project	and	available	funding	limited	what	was	possible	to	
achieve,	and	the	decision	not	to	recruit	psychosis-only	comparison	participants	was	taken	to	
maximise	the	number	of	individuals	with	ASD-P	that	could	be	recruited.		
	
Final	remarks	and	suggestions	for	future	research	
What	is	clear	from	this	research	is	that	individuals	who	experience	concurrent	ASD	and	
psychotic	illness	exist	and	are	treated	in	mental	health	services.	Sometimes,	the	ASD	has	not	been	
recognised	prior	to	the	first	onset	of	psychiatric	illness,	and	thus	clinicians	on	the	front	line	are	often	
left	treating	not	only	the	psychosis	but	are	also	facing	the	challenges	of	identifying	an	underlying	
ASD	(6).	Mental	health	services	in	the	UK	are	yet	to	be	fully	equipped	to	support	people	with	both	
psychotic	illness	and	ASD.	Thus,	for	many,	their	psychotic	illness	will	be	treated	but	their	quality	of	
life	will	suffer	because	there	may	be	no	aftercare	or	support	services	tailored	to	the	needs	of	those	
with	ASD.	Whilst	not	captured	in	this	study,	this	type	of	variability	emerged	in	our	discussions	with	
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participants	and	should	be	an	area	of	urgent	action	at	a	procedural	and	policy	level.	In	addition,	
more	research	is	needed	into	aetiological	and	phenotypic	overlaps	between	ASD	and	psychosis,	
utilising	a	dual-diagnosis	cohort	compared	with	two	control	groups,	each	singly	diagnosed	with	ASD	
or	psychosis.	The	development	of	a	multi-dimensional	model	for	understanding	the	relationship	
between	these	two	conditions	would	require	cohorts	to	be	described	not	solely	by	diagnosis,	but	
using	dimensional	measures.	Peralta	and	Cuesta	(35)	have	summarized	the	complexities	inherent	in	
creating	a	dimensional	measure	of	psychosis,	but	a	promising	effort	to	develop	an	effective	system	
was	presented	by	Läge	et	al.	(36).	Their	approach	involved	categorical	and	dimensional	aspects,	
encompassing	affective	and	psychotic	features.	It	is	not	difficult	to	picture	how	integrating	features	
of	ASD	into	such	a	model	would	be	possible,	given	the	known	dimensions	within	ASD	and	the	well-
validated	measures	already	in	use	with	this	population.	
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Table	1.	Demographic	profile	of	ASD-psychosis	(ASD-P)	and	ASD-no	psychosis	(ASD-NP)	groups	used	for	
comparison	of	Autism	Diagnostic	Interview-Revised	responses.	ns=non-significant	
	 	 ASD-P	(N=75)	 ASD-NP	(N=69)	 Group	Differences	
Age	
	
Mean	 27.7	 27.8	 ns	
	 Range	(years)	 17-55	 18-49	 	
	 Standard	deviation	 7.5	 7.6	 	
Gender	(%M)	 	 84%	 46%	 X²(1)=22.7,	p<0.001	
	
Verbal	IQ	
	
Mean	 95.5	 113.3	 Dif=-17.5	(95%	CI=	
-24,	-11),	p<0.001	
	 Range	 55-133	 67-137	 	
	 Standard	deviation	 23.1	 14.7	 	
	
	
	
	
Table	2.	Results	of	the	MANCOVA	applied	to	scales	A,	B,	and	C	of	the	ADI-R.	Also	shown	are	the	three	
univariate	regressions	separately	relating	each	of	the	ADI-R	scales	to	the	covariates	(all	based	on	type	III	sums	
of	squares).	Partial	η²	is	a	measure	of	effect	size	(small:	0.01;	medium:	0.09;	large:	0.25;	based	on	the	square	of	
the	Pearson	correlation	effect	sizes	from	Cohen	(19)).	VIQ=verbal	IQ.	
Term	
Multivariate	analysis	 Univariate	analysis	
Pillai	
statistic	 Significance	 η²	 ADIR	scale	A	 ADIR	scale	B	 ADIR	scale	C	
Gender	 0.07	
F(3,137)=3.4,	
p=0.019	 0.07	
F(1,139)=5.7,	
p=0.018,	η²=0.04	
F(1,139)=9.0,	
p=0.003,	η²=0.06	
F(1,139)=4.9,	
p=0.029,	η²=0.03	
Age	 0.05	
F(3,137)=2.2,	
p=0.090	 0.05	
F(1,139)=5.2,	
p=0.024,	η²=0.04	
F(1,139)=1.3,	
p=0.253,	η²=0.01	
F(1,139)=2.4,	
p=0.126,	η²=0.02	
VIQ	 0.10	
F(3,137)=4.9,	
p=0.003	 0.10	
F(1,139)=6.8,	
p=0.001,	η²=0.05	
F(1,139)=15.0,	
p<0.001,	η²=0.10	
F(1,139)=2.1,	
p=0.150,	η²=0.01	
Group	 0.07	
F(3,137)=3.2,	
p=0.025	 0.07	
F(1,139)=3.3,	
p=0.070,	η²=0.02	
F(1,139)=4.0,	
p=0.046,	η²=0.03	
F(1,139)=8.7,	
p=0.004,	η²=0.06	
Multivariate	η²=1-Λ1/s	where	Λ=Wilk's	lambda	and	s=minimum	of	the	number	of	levels	of	the	factor	minus	1,	or	
the	number	of	dependent	variables	(here,	s=1	for	continuous	variables)	(20).		
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Figure	1.	Broad	symptom	categories	and	their	prevalence	in	the	ASD-P	sample.	*Mania	includes	both	
hypomanic	and	manic	symptoms	(defined	by	duration).	
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Figure	1.	Prevalence	of	DSM-IV-TR	diagnosis	by	group.	This	figure	compares	the	prevalence	of	DSM-IV-TR	
diagnosed	psychosis	between	a	general	psychiatric	sample	(ÆSOP	study	-	P)	(18)	and	a	group	of	people	with	
ASD	and	co-morbid	psychosis	(ASD-P).	‘Schizophrenia’	here	includes	schizophrenia,	schizophreniform,	and	
schizoaffective	disorders.	Affective	psychosis	includes	those	with	major	depressive	episode	with	psychotic	
features,	manic	episode	with	psychotic	features,	and	bipolar	disorder	with	psychosis.	‘Other	psychosis’	
includes	psychotic	disorder	not	otherwise	specified,	which	was	present	in	44%	of	the	ASD-P	sample.	†Of	the	
full	ASD-P	data	set	(N=75),	4	had	a	DSM-IV-TR	diagnosis	of	major	depressive	episode	without	psychotic	
features	and	were	thus	excluded	from	this	comparison.	
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